6-(cyclohexylamino)-N-(1H-indol-5-yl)pyrimidine-4-carboxamide | 1219937-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-(cyclohexylamino)-N-(1H-indol-5-yl)pyrimidine-4-carboxamide
• CAS: 1219937-82-2
• 化学式: C₁₉H₂₁N₅O
• 分子量: 335.409
• InChiKey: XOEUJDNRYAEWRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  82.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-氨基吲哚 、 6-(cyclohexylamino)pyrimidine-4-carboxylic acid 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-(cyclohexylamino)-N-(1H-indol-5-yl)pyrimidine-4-carboxamide
  参考文献：
  名称：

  Discovery of a novel series of potent S1P1 agonists

  摘要：

  The discovery of a novel series of S1P1 agonists is described. Starting from a micromolar HTS positive, iterative optimization gave rise to several single-digit nanomolar S1P1 agonists. The compounds were able to induce internalization of the S1P1 receptor, and a selected compound was shown to be able to induce lymphopenia in mice after oral dosing. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.102

文献信息

• 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis
  申请人：Bombrun Agnes

  公开号：US20100210619A1

  公开（公告）日：2010-08-19

  The invention relates to compounds of formula (I): wherein X, W, Q, R, R 1 and R 2 have the meanings given in claim 15. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

  该发明涉及式(I)的化合物：其中X、W、Q、R、R1和R2的含义如权利要求15所述。该化合物在治疗自身免疫性疾病（如多发性硬化症）等方面是有用的。
• 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Merck Serono Sa

  公开号：US20130109669A1

  公开（公告）日：2013-05-02

  The invention relates to compounds of formula (I): wherein X, W, Q, R, R 1 and R 2 have the meanings given in claim 1 . The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

  本发明涉及式(I)的化合物：其中X、W、Q、R、R1和R2具有权利要求1中给出的含义。该化合物可用于治疗自身免疫性疾病，如多发性硬化症。
• US8399448B2
  申请人：——

  公开号：US8399448B2

  公开（公告）日：2013-03-19
• US9150519B2
  申请人：——

  公开号：US9150519B2

  公开（公告）日：2015-10-06
• Discovery of a novel series of potent S1P1 agonists
  作者：Stefano Crosignani、Agnes Bombrun、David Covini、Maurizio Maio、Delphine Marin、Anna Quattropani、Dominique Swinnen、Don Simpson、Wolfgang Sauer、Bernard Françon、Thierry Martin、Yves Cambet、Anthony Nichols、Isabelle Martinou、Fabienne Burgat-Charvillon、Delphine Rivron、Cristina Donini、Olivier Schott、Valerie Eligert、Laurence Novo-Perez、Pierre-Alain Vitte、Jean-François Arrighi

  DOI：10.1016/j.bmcl.2010.01.102

  日期：2010.3

  The discovery of a novel series of S1P1 agonists is described. Starting from a micromolar HTS positive, iterative optimization gave rise to several single-digit nanomolar S1P1 agonists. The compounds were able to induce internalization of the S1P1 receptor, and a selected compound was shown to be able to induce lymphopenia in mice after oral dosing. (C) 2010 Elsevier Ltd. All rights reserved.